- Home
- MSPR vs ENVB Comparison
MSPR vs ENVB Comparison
Compare MSPR & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSPR
- ENVB
- Stock Information
- Founded
- MSPR 2014
- ENVB 1994
- Country
- MSPR United States
- ENVB United States
- Employees
- MSPR N/A
- ENVB N/A
- Industry
- MSPR
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- MSPR
- ENVB Health Care
- Exchange
- MSPR NYSE
- ENVB Nasdaq
- Market Cap
- MSPR 4.9M
- ENVB 4.1M
- IPO Year
- MSPR N/A
- ENVB N/A
- Fundamental
- Price
- MSPR $2.16
- ENVB $0.35
- Analyst Decision
- MSPR
- ENVB Strong Buy
- Analyst Count
- MSPR 0
- ENVB 1
- Target Price
- MSPR N/A
- ENVB $10.00
- AVG Volume (30 Days)
- MSPR 203.5K
- ENVB 1.0M
- Earning Date
- MSPR 11-14-2024
- ENVB 11-14-2024
- Dividend Yield
- MSPR N/A
- ENVB N/A
- EPS Growth
- MSPR N/A
- ENVB N/A
- EPS
- MSPR N/A
- ENVB N/A
- Revenue
- MSPR $10,734,000.00
- ENVB N/A
- Revenue This Year
- MSPR $293,208.70
- ENVB N/A
- Revenue Next Year
- MSPR N/A
- ENVB N/A
- P/E Ratio
- MSPR N/A
- ENVB N/A
- Revenue Growth
- MSPR 217.86
- ENVB N/A
- 52 Week Low
- MSPR $1.43
- ENVB $0.30
- 52 Week High
- MSPR $66.00
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- MSPR N/A
- ENVB 46.61
- Support Level
- MSPR N/A
- ENVB $0.35
- Resistance Level
- MSPR N/A
- ENVB $0.39
- Average True Range (ATR)
- MSPR 0.00
- ENVB 0.05
- MACD
- MSPR 0.00
- ENVB -0.00
- Stochastic Oscillator
- MSPR 0.00
- ENVB 19.56
About MSPR MSP RECOVERY INC
MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.